SUPERNUS PHARMACEUTICALS

Latest clinical program signals indexed for SUPERNUS PHARMACEUTICALS.

1. 817P203 — Phase 2

   Jun 8, 2026
   Clinical update →

2. Topiramate IR — Phase 1

   Jun 8, 2026
   Clinical update →

3. Phase 2; Low Dose MYOBLOC — Phase 3

   Jun 8, 2026
   Clinical update →

4. Phase 2; Low Dose MYOBLOC (15,000 Units) — Phase 3

   Jun 8, 2026
   Clinical update →

5. MYOBLOC Low Dose — Phase 3

   Jun 8, 2026
   Clinical update →

6. IR-TPM (Topamax) — Phase 2

   Jun 8, 2026
   Clinical update →

7. Gocovri (extended-release amantidine) — Phase 2

   Jun 8, 2026
   Clinical update →

8. Botulinum Toxin Type B (Myobloc) — Phase 2

   Jun 8, 2026
   Clinical update →

1. 2025-520587-18-00

   817P203

   Phase 2 · active · small_molecule

   Focal Onset Seizures

   CTIS ↗
2. NCT00515437

   Botulinum Toxin Type B (Myobloc)

   Phase 2 · completed · mab

   Drooling

   CT.gov ↗
3. NCT00626236

   SPN-810

   Phase 2 · completed · small_molecule

   Attention Deficit Disorder With Hyperactivity

   CT.gov ↗
4. NCT00702754

   Botulinum Toxin Type B

   Approved · completed · mab

   Cervical Dystonia

   CT.gov ↗
5. NCT00772603

   Placebo

   Phase 3 · completed · small_molecule

   Epilepsies, Partial

   CT.gov ↗
6. NCT00908349

   Oxcarbazepine XR

   Phase 3 · completed · small_molecule

   Partial Epilepsy

   CT.gov ↗
7. NCT00918047

   SPN-804O

   Phase 1 · completed · small_molecule

   Epilepsies, Partial

   CT.gov ↗
8. NCT01107496

   IR Viloxazine

   Phase 2 · completed · small_molecule

   Attention-Deficit/Hyperactivity Disorder (ADHD)

   CT.gov ↗
9. NCT01114854

   Topiramate IR

   Phase 1 · completed · small_molecule

   Epilepsy

   CT.gov ↗
10. NCT01284530

    TPM XR

    Phase 2 · completed · small_molecule

    Epilepsy

    CT.gov ↗
11. NCT01364662

    SPN-810

    Phase 2 · completed · small_molecule

    Impulsive Aggression Comorbid With ADHD

    CT.gov ↗
12. NCT01416064

    Molindone

    Phase 2 · completed · small_molecule

    Impulsive Aggression Comorbid With ADHD in Children

    CT.gov ↗
13. NCT01770145

    APOKYN

    Approved · terminated · small_molecule

    Parkinson's Disease

    CT.gov ↗
14. NCT01994109

    MYOBLOC

    Phase 3 · completed · small_molecule

    Sialorrhea

    CT.gov ↗
15. NCT02023606

    SPN-810M

    Phase 1 · completed · small_molecule

    Impulsive Aggression Comorbid With ADHD

    CT.gov ↗
16. NCT02052739

    SAGE-547

    Phase 3 · completed · small_molecule

    Super-refractory Status Epilepticus

    CT.gov ↗
17. NCT02285504

    SAGE-547

    Phase 2 · completed · small_molecule

    Postpartum Depression

    CT.gov ↗
18. NCT02339064

    apomorphine infusion

    Phase 3 · active · small_molecule

    Idiopathic Parkinson's Disease

    CT.gov ↗
19. NCT02477618

    SAGE-547

    Phase 3 · completed · small_molecule

    Super-refractory Status Epilepticus

    CT.gov ↗
20. NCT02549573

    APOKYN

    Approved · terminated · small_molecule

    Parkinson's Disease

    CT.gov ↗
21. NCT02610868

    MYOBLOC

    Phase 3 · completed · small_molecule

    Sialorrhea

    CT.gov ↗
22. NCT02614547

    SAGE-547

    Phase 2 · completed · small_molecule

    Severe Postpartum Depression

    CT.gov ↗
23. NCT02618408

    SPN-810 (18 mg)

    Phase 3 · completed · small_molecule

    Attention Deficit Hyperactivity Disorder (ADHD)

    CT.gov ↗
24. NCT02618434

    SPN-810 (18 mg)

    Phase 3 · completed · small_molecule

    Attention Deficit Hyperactivity Disorder (ADHD)

    CT.gov ↗
25. NCT02633527

    Placebo

    Phase 3 · completed · small_molecule

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    CT.gov ↗
26. NCT02691182

    SPN-810

    Phase 3 · terminated · small_molecule

    Attention Deficit Hyperactivity Disorder (ADHD)

    CT.gov ↗
27. NCT02736656

    SPN-812

    Approved · active · small_molecule

    Attention-Deficit/Hyperactivity Disorder

    CT.gov ↗
28. NCT02942004

    Placebo

    Phase 3 · completed · small_molecule

    Postpartum Depression

    CT.gov ↗
29. NCT02942017

    Placebo

    Phase 3 · completed · small_molecule

    Postpartum Depression

    CT.gov ↗
30. NCT03156439

    BIS-001 ER

    Phase 1 · completed · small_molecule

    Epilepsy, Complex Partial

    CT.gov ↗
31. NCT03247517

    Placebo

    Phase 3 · completed · small_molecule

    ADHD

    CT.gov ↗
32. NCT03247530

    Placebo

    Phase 3 · completed · small_molecule

    ADHD

    CT.gov ↗
33. NCT03247543

    Placebo

    Phase 3 · completed · small_molecule

    ADHD

    CT.gov ↗
34. NCT03247556

    Placebo

    Phase 3 · completed · small_molecule

    ADHD

    CT.gov ↗
35. NCT03280342

    IR-TPM (Topamax)

    Phase 2 · terminated · small_molecule

    Migraine

    CT.gov ↗
36. NCT03474770

    BIS-001ER

    Phase 2 · active · small_molecule

    Focal Impaired Awareness Seizures

    CT.gov ↗
37. NCT03597503

    SPN-810

    Phase 3 · terminated · small_molecule

    Attention Deficit Hyperactivity Disorder

    CT.gov ↗
38. NCT03638466

    SPN-810

    Phase 3 · terminated · small_molecule

    Attention Deficit Hyperactivity Disorder (ADHD)

    CT.gov ↗
39. NCT03665038

    Brexanolone

    Phase 3 · completed · small_molecule

    Post Partum Depression

    CT.gov ↗
40. NCT03770780

    SAGE-718

    Phase 1 · completed · small_molecule

    Healthy Volunteer

    CT.gov ↗
41. NCT03771586

    SAGE-718

    Phase 1 · completed · small_molecule

    Healthy Volunteer

    CT.gov ↗
42. NCT03787758

    SAGE-718

    Phase 2 · completed · small_molecule

    Huntington Disease

    CT.gov ↗
43. NCT03844906

    SAGE-718

    Phase 1 · completed · small_molecule

    Healthy Volunteer

    CT.gov ↗
44. NCT04016779

    Placebo

    Phase 3 · completed · small_molecule

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    CT.gov ↗
45. NCT04016792

    Placebo

    Phase 3 · completed · small_molecule

    ADHD

    CT.gov ↗
46. NCT04050293

    SPN-538

    Approved · terminated · small_molecule

    Migraine Disorders

    CT.gov ↗
47. NCT04099667

    Phase 2; Low Dose MYOBLOC (15,000 Units)

    Phase 3 · terminated · small_molecule

    Spasticity

    CT.gov ↗
48. NCT04143217

    SPN-812

    Approved · active · small_molecule

    Attention-Deficit/Hyperactivity Disorder

    CT.gov ↗
49. NCT04476017

    SAGE-718

    Phase 2 · completed · small_molecule

    Parkinson Disease

    CT.gov ↗
50. NCT04602624

    SAGE-718

    Phase 2 · completed · small_molecule

    Alzheimer Disease

    CT.gov ↗
51. NCT04781140

    100mg SPN-812

    Approved · active · small_molecule

    Attention-Deficit/Hyperactivity Disorder

    CT.gov ↗
52. NCT04786990

    SPN-812

    Approved · completed · small_molecule

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    CT.gov ↗
53. NCT04815967

    Phase 2; Low Dose MYOBLOC

    Phase 3 · active · small_molecule

    Spasticity

    CT.gov ↗
54. NCT05049343

    SAGE-904

    Phase 1 · completed · small_molecule

    Healthy Volunteer

    CT.gov ↗
55. NCT05059600

    ZULRESSO®

    Approved · completed · small_molecule

    Postpartum Depression

    CT.gov ↗
56. NCT05066672

    NV-5138

    Phase 2 · completed · small_molecule

    Treatment Resistant Depression

    CT.gov ↗
57. NCT05097079

    MYOBLOC Low Dose

    Phase 3 · terminated · small_molecule

    Sialorrhea

    CT.gov ↗
58. NCT05102552

    SPN-817, Treatment B

    Phase 1 · completed · small_molecule

    Healthy Volunteer

    CT.gov ↗
59. NCT05107128

    SAGE-718

    Phase 3 · terminated · small_molecule

    Huntington's Disease

    CT.gov ↗
60. NCT05152680

    [14C]-NV-5138

    Phase 1 · completed · small_molecule

    Healthy Volunteers

    CT.gov ↗
61. NCT05318937

    SAGE-718-matching placebo

    Phase 2 · completed · small_molecule

    Parkinson Disease

    CT.gov ↗
62. NCT05358821

    SAGE-718

    Phase 2 · completed · small_molecule

    Huntington Disease

    CT.gov ↗
63. NCT05384977

    [14C]-NV-5138

    Phase 1 · completed · small_molecule

    Healthy Volunteers

    CT.gov ↗
64. NCT05518578

    SPN-817

    Phase 2 · active · small_molecule

    Epilepsy

    CT.gov ↗
65. NCT05619692

    SAGE-718

    Phase 2 · completed · small_molecule

    Mild Cognitive Impairment

    CT.gov ↗
66. NCT05645432

    Brexanolone

    Phase 2 · completed · small_molecule

    Tinnitus

    CT.gov ↗
67. NCT05655520

    SAGE-718

    Phase 3 · terminated · small_molecule

    Huntington's Disease

    CT.gov ↗
68. NCT06185985

    SPN-812

    Approved · active · small_molecule

    Attention-Deficit/Hyperactivity Disorder

    CT.gov ↗
69. NCT06235905

    NV-5138

    Phase 2 · completed · small_molecule

    Major Depressive Disorder

    CT.gov ↗
70. NCT06259331

    SPN-812 (600mg, QD)

    Approved · completed · small_molecule

    Healthy Lactating Women

    CT.gov ↗
71. NCT06798896

    SPN-817

    Phase 2 · active · small_molecule

    Focal Onset Seizures

    CT.gov ↗
72. NCT07125222

    Gocovri (extended-release amantidine)

    Phase 2 · active · small_molecule

    Radiation Encephalopathy

    CT.gov ↗
73. NCT07141329

    SPN-817

    Phase 2 · active · small_molecule

    Focal Onset Seizures

    CT.gov ↗
74. NCT07226661

    SPN-821 2400 mg

    Phase 2 · active · small_molecule

    Major Depressive Disorder (MDD)

    CT.gov ↗